Public Market Listing
CLN GPW
GPW primary exchange listing
External market data link · No third-party exchange redistribution
Assets (2 total) 2 Total Assets
0 Approved
0 Phase 3 / Filed
2 Phase 1–2 / Early
3 Diseases
Disease: All diseases (2) Type 2 Diabetes (1) Parkinson's Disease (1) Schizophrenia (1)
Stage: All stages (2) Approved / Phase 4 (0) Phase 3 / Filed (0) Phase 2 Phase 1 / Preclinical
Quick filter: All (2) Type 2 Diabetes (1) Parkinson's Disease (1) Schizophrenia (1)
Showing 2 of 2 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 2 GPR40 / FFAR1 Small molecule
Phase 2 PDE10A Small molecule
Parkinson's Disease Schizophrenia
Upcoming events No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports Annual history (5 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $65M — — $21M report ↗
View 4 more years